Volume | 2,501,716 |
|
|||||
News | - | ||||||
Day High | 10.66 | Low High |
|||||
Day Low | 10.24 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.27 | 10.24 | 10.66 | 10.61 | 10.33 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
17,284 | 2,501,716 | $ 10.48 | $ 26,216,653 | - | 9.70 - 14.57 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:29:19 | formt | 131 | $ 10.61 | USD |
Amicus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.1B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Amicus Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.07 | 11.07 | 10.24 | 10.57 | 2,507,679 | -0.46 | -4.16% |
1 Month | 11.72 | 11.93 | 10.24 | 11.27 | 2,360,623 | -1.11 | -9.47% |
3 Months | 12.75 | 14.03 | 10.24 | 12.37 | 3,045,348 | -2.14 | -16.78% |
6 Months | 10.66 | 14.57 | 9.70 | 12.19 | 3,009,663 | -0.05 | -0.47% |
1 Year | 11.83 | 14.57 | 9.70 | 12.26 | 2,750,532 | -1.22 | -10.31% |
3 Years | 9.90 | 14.57 | 5.91 | 10.93 | 2,693,781 | 0.71 | 7.17% |
5 Years | 12.62 | 25.39 | 5.91 | 11.60 | 2,731,488 | -2.01 | -15.93% |
Amicus Therapeutics Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |